Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lg-190178 SCHEMBL30771984 | 1.00 | VDR (1.00) | VDRAR | |
| Lg-190178 SCHEMBL30771985 | 1.00 | VDR (1.00) | VDRAR | |
| Lg-190178 SCHEMBL3392118 | 1.00 | VDR (1.00) | VDRAR | |
| SCHEMBL5156306 | 0.89 | VDR (0.80) | VDRAR | |
| SCHEMBL5153931 | 0.89 | VDR (0.80) | VDRAR | |
| SCHEMBL16183082 | 0.89 | VDR (0.80) | VDRAR | |
| SCHEMBL16183077 | 0.88 | VDR (0.79) | VDRAR | |
| SCHEMBL5159155 | 0.87 | VDR (0.77) | VDRAR | |
| SCHEMBL5157103 | 0.87 | VDR (0.77) | VDRAR | |
| SCHEMBL1050785 | 0.87 | VDR (0.77) | VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376264-B2 | Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376264-B2 | Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment | BRD9, BRD2, BRD3 | VDR 5/4885AR 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.